Xtx Topco LTD Spero Therapeutics, Inc. Transaction History

Xtx Topco LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$1.35 - $1.79 $68,786 - $91,205	-50,953 Reduced 77.24%	15,013 $25,000
Q4 2023 Feb 13, 2024	BUY	$1.0 - $1.47 $7,598 - $11,169	7,598 Added 13.02%	65,966 $96,000
Q3 2023 Nov 13, 2023	SELL	$1.2 - $1.63 $57,619 - $78,266	-48,016 Reduced 45.13%	58,368 $70,000
Q2 2023 Aug 14, 2023	SELL	$1.42 - $1.95 $19,137 - $26,280	-13,477 Reduced 11.24%	106,384 $154,000
Q1 2023 May 12, 2023	SELL	$1.35 - $2.0 $306,278 - $453,746	-226,873 Reduced 65.43%	119,861 $173,000
Q4 2022 Feb 14, 2023	BUY	$1.55 - $2.12 $537,437 - $735,076	346,734 New	346,734 $599,000
Q2 2022 Aug 15, 2022	SELL	$0.74 - $7.44 $9,812 - $98,654	-13,260 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$7.87 - $15.15 $104,356 - $200,889	13,260 New	13,260 $115,000

13.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $30.2M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

Stay updated on Xtx Topco LTD with notifications on news.